MEI Pharma (NASDAQ:MEIP – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.48) EPS for the quarter, Zacks reports.
MEI Pharma Stock Performance
Shares of NASDAQ MEIP traded down $0.12 during midday trading on Friday, hitting $2.60. 290 shares of the stock traded hands, compared to its average volume of 11,276. The company has a market cap of $17.32 million, a PE ratio of -0.37 and a beta of 0.79. MEI Pharma has a one year low of $2.30 and a one year high of $4.82. The business has a 50 day moving average price of $2.68 and a two-hundred day moving average price of $2.90.
Analysts Set New Price Targets
Separately, StockNews.com began coverage on MEI Pharma in a report on Tuesday. They set a “buy” rating for the company.
MEI Pharma Company Profile
MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.
Further Reading
- Five stocks we like better than MEI Pharma
- What is a buyback in stocks? A comprehensive guide for investors
- NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
- 3 Small Caps With Big Return Potential
- Up 50% in January, Twilio’s Pullback is the Time to Buy
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
